Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-23T02:04:40.055Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevalence and covid 19 vaccination rate in a population of patients with schizophrenia and a substance use disorder

Published online by Cambridge University Press:  01 September 2022

S.L. Romero Guillena ,
I. De Burgos Berdud ,
R. Gálvez Medina  and
E. Serrano Rodriguez
S.L. Romero Guillena*
Affiliation:
UGC Salud Mental Virgen Macarena,, Psychiatry, seville, Spain
I. De Burgos Berdud
Affiliation:
UGC Salud Mental Virgen Macarena,, Psychiatry, seville, Spain
R. Gálvez Medina
Affiliation:
UGC Salud Mental Virgen Macarena,, Psychiatry, seville, Spain
E. Serrano Rodriguez
Affiliation:
UGC Salud Mental Virgen Macarena,, Psychiatry, seville, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

As of August 27th, 2021, the diagnosed cases of COVID 19 in Spain are 4 758 003 with a prevalence of 10.03%. 68.4% of the Spanish population is fully vaccinated

Objectives

Primary: To compare the prevalence of COVID infection in a cohort of patients with schizophrenia to patients with a dual diagnosis of schizophrenia and substance use disorder Secondary: To compare the rate of fully vaccinated patients diagnosed with schizophrenia with and without a coexisting substance use disorder.

Methods

Retrospective descriptive study. The population in study is made up of patients with schizophrenia (46) and dual diagnosis schizophrenia (28) (following DSM 5 criteria) Confirmed cases were those cases with positive PCR

Results

There was not a stadistically significant difference in the prevalence of COVID 19 infection between both groups of patients. The prevalence of COVID infection among the dual diagnosis schizophrenia was 3.57% compared to 6.5% in those without coexisting substance abuse disorder. Relative to vaccination rate, we didn’t find a stadistically significant difference between both groups. However, there was a higher vaccination rate in the dual diagnosis schizophrenia group (82.12%) compared to the non-dual diagnosis schizophrenia group (69.56%)

Conclusions

The prevalence of COVID 19 infection in the dual diagnosis schizophrenia cohort is 3.57% and in the group of patients with schizophrenia without substance abuse disorder is 6,5%. In those with dual diagnosis schizophrenia the vaccination rate was un 82.12%. It was 69.56% in those without coexisting substance abuse disorder.

Disclosure

No significant relationships.

Keywords

schizophréniavaccination ratecovid 19Prevalence
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S267
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.